🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Pembrolizumab placebo (saline)

Found 54 matching trials

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

PHASE3

The purpose of this study is to assess the efficacy and safety of the combi...

Status

Completed

Location

University of South Alabama, Mitchell Cancer Institute ( Site 0065)

Start Date

2019-05-02

Trial ID

NCT03834506

Treatments Being Tested

Pembrolizumab Docetaxel Prednisone Placebo Dexamethasone

Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer

PHASE2

The primary scientific question of interest of this study is whether the co...

Status

Withdrawn

Location

Multiple Locations

Start Date

2023-09-15

Trial ID

NCT05809895

Treatments Being Tested

Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

PHASE3

The safety and efficacy of pembrolizumab plus the investigator's choice of ...

Status

Active Not Recruiting

Location

University of Alabama at Birmingham-Medicine ( Site 0065)

Start Date

2021-06-18

Trial ID

NCT04895358

Treatments Being Tested

pembrolizumab paclitaxel nab-paclitaxel liposomal doxorubicin capecitabine normal saline dextrose

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

PHASE3

The purpose of this study is to determine the efficacy and safety of pembro...

Status

Completed

Location

Anhui Provincial Hospital ( Site 0032)

Start Date

2017-04-27

Trial ID

NCT03062358

Treatments Being Tested

pembrolizumab placebo best supportive care (BSC)

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

PHASE3

Researchers are looking for new ways to treat Limited-Stage Small Cell Lung...

Status

Active Not Recruiting

Location

Ironwood Cancer & Research Centers ( Site 0007)

Start Date

2020-12-08

Trial ID

NCT04624204

Treatments Being Tested

Pembrolizumab 200 mg Pembrolizumab 400 mg Pembrolizumab placebo (saline)Pembrolizumab placebo (saline)Olaparib 300 mg BID Olaparib matching placebo Etoposide 100 mg/m^2 Platinum, investigator's choice Standard Thoracic Radiotherapy Prophylactic Cranial Irradiation (PCI)

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

PHASE2

This is a multi-center study in patients with recurrent or metastatic HPV16...

Status

Withdrawn

Location

Multiple Locations

Start Date

2024-04-18

Trial ID

NCT06099418

Treatments Being Tested

VB10.16 Atezolizumab Injection [Tecentriq]Placebo

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

PHASE3

The purpose of this study is to determine the efficacy and safety of pembro...

Status

Completed

Location

UCLA Medical Center ( Site 0273)

Start Date

2017-04-05

Trial ID

NCT03040999

Treatments Being Tested

Pembrolizumab Placebo Cisplatin Accelerated Fractionation (AFX) Radiotherapy Standard Fractionation (SFX) Radiotherapy

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

PHASE3

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475)...

Status

Completed

Location

Banner MD Anderson Cancer Center ( Site 0026)

Start Date

2019-05-28

Trial ID

NCT03867084

Treatments Being Tested

Pembrolizumab Placebo

Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy

PHASE3

The goal of this trial is to test whether patients with stage III papillary...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2023-12-01

Trial ID

NCT06146777

Treatments Being Tested

Pembrolizumab Placebo

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

PHASE2

The main purpose of this study is to compare pembrolizumab/vibostolimab cof...

Status

Completed

Location

Cedars-Sinai Medical Center ( Site 2522)

Start Date

2021-04-20

Trial ID

NCT04725188

Treatments Being Tested

Pembrolizumab/Vibostolimab coformulation Docetaxel Placebo

Previous Next